Maintainers and developers are now using AI to help build Linux. Simultaneously, Rust has graduated to being a co-equal language with C for mainstream Linux development. However, the programming world ...
A United States District Court judge on Thursday ruled that the Federal Emergency Management Agency (FEMA) was wrong to cancel a program that has funded infrastructure resiliency efforts in ...
ADVANCING MOST-FAVORED-NATION (MFN) PRICING: Today, President Donald J. Trump announced the latest in a series of the most significant actions ever taken by our Federal government to lower ...
Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...
Virginia Tech researchers have shown that memory loss in aging may be reversible. Using CRISPR tools, they corrected molecular disruptions in the hippocampus and amygdala, restoring memory in older ...
Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...
Senate Democrats unveiled a proposal on Wednesday evening that would reverse the nearly $1 trillion in cuts to Medicaid implemented under President Donald Trump's One Big Beautiful Bill, among other ...
Defense technology company Booz Allen Hamilton Inc. today announced the launch of Vellox Reverser, an artificial intelligence cloud product that protects organizations from malware as cyberattacks ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio ...
Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – Rallybio Corporation (Nasdaq: RLYB), a ...